Yale Cancer Center ASCO Participation – 2016 Annual Meeting

Friday, June 3rd

Extended Education Session:
3:45 PM – 4:05 PM
Location: S404
Practical Tips for Academic, Private, and Industry Career Tracks: Negotiating Contracts and Education Debt Management
Roy Herbst, MD, PhD

Saturday, June 4th

Poster Sessions: Lung Cancer—Non-Small Cell Metastatic
8:00 AM - 11:30 AM
Location: Hall A

Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors
Scott Gettinger, MD

Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer
Patricia Gaule, PhD

HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies
Bing Xia, M.D

Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status
Scott N. Gettinger, MD

Poster Sessions: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
8:00 AM - 11:30 AM
Location: Hall A

Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort
Daniel J Boffa, MD

Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)
Anne C. Chiang, MD, PhD
Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in Small Cell Lung Cancer (SCLC)
Kurt Alex Schalper, MD/PhD

Poster Session: Head and Neck Cancer
1:00 PM – 4:30 PM
Location: Hall A

Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck
Aarti K. Bhatia, MD, MPH

Poster Session: Health Services Research and Quality of Care
1:00 PM – 4:30 PM
Location: Hall A

Bone density screening in postmenopausal women with early-stage breast cancer on aromatase inhibitors
Jamie Stratton, MD

Poster Discussion Session: Health Services Research and Quality of Care
5:03 PM – 5:15 PM
Location: S404

Developing and Incorporating Guidelines Into Cancer Care
Cary Gross, MD

Poster Discussion Session: Central Nervous System Tumors
5:39 PM - 5:51 PM
Location: S102

Bench Versus Bedside in the Management of Brain Metastases
Ranjit Bindra, MD, PhD

Sunday, June 5th

Highlights of the Day Session: Highlights of the Day Session I
8:10 AM - 8:30 AM
Location: Hall D1

Developmental Therapeutics and Translational Research—Immunotherapy
Mario Sznol, MD
Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC
Roy S. Herbst, MD, PhD

A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results
Roy S. Herbst, MD, PhD

Association between DNA level aberrations and immune cell infiltration in breast cancer
Anton Mikhailovich Safonov, BS

Randomized trial assessing the impact of survivorship care plans on the quality of care for childhood cancer survivors
Cary Philip Gross, MD

T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab
Hannah Elizabeth Dzimitrowicz, BA

Why the Quality Oncology Practice Initiative Matters: Or Is It Just About Cost?
Anne C. Chiang, MD, PhD
Monday, June 6th

**Poster Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia**
8:00 AM - 11:30 AM
Location: Hall A

*Impact of leucovorin on mucositis and skin reactions in pts with peripheral t-cell Lymphoma (PTCL) and cutaneous t-cell lymphoma (CTCL) treated with pralatrexate*
Francine M. Foss, MD

**Oral Abstract Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics**
9:36 AM - 9:48 AM
Location: E354b

*Novel Strategies to Target DNA Repair*
Patricia LoRusso, DO

**Poster Session: Genitourinary (Nonprostate) Cancer**
1:00 PM - 4:30 PM
Location: Hall A

*Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC)*
Daniel Peter Petrylak, MD

**Poster Sessions: Gynecologic Cancer**
1:00 PM - 4:30 PM
Location: Hall A

*Randomized trial of exercise vs. usual care on cancer biomarkers in ovarian cancer survivors: The Women’s Activity and Lifestyle Study in Connecticut (WALC)*
Brenda Cartmel, PhD

*Mutational landscape of uterine and ovarian carcinosarcomas*
Gulden Menderes, MD

*Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA)*
Alessandro Santin, MD
Poster Sessions: Patient and Survivor Care
1:00 PM - 4:30 PM
Location: Hall A

Impact of weight loss and exercise on VEGF levels in breast cancer survivors
Tara Beth Sanft, MD

Association of length of hospice enrollment with regional variation in end-of-life care expenditures
Shi-Yi Wang, MD, PhD

Associations of pre- and post-cancer depression with end-of-life cancer care intensity
Kathy Cao Doan, BA

Poster Session: Tumor Biology
1:00 PM - 4:30 PM
Location: Hall A

Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC)
Kurt Alex Schalper, MD/PhD

Tuesday, June 7th

Oral Abstract Session: Cancer Prevention, Hereditary Genetics, and Epidemiology
10:12 AM - 10:24 AM
Location: S102

Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590)
Aarti K. Bhatia, MD, MPH